CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, Oxford University, Oxford, UK.
Istituto Oncologico Veneto I.R.C.C.S., Padova, Italy.
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2442-2455. doi: 10.1007/s00259-018-4146-5. Epub 2018 Sep 17.
Effective treatment for pancreatic cancer remains challenging, particularly the treatment of pancreatic ductal adenocarcinoma (PDAC), which makes up more than 95% of all pancreatic cancers. Late diagnosis and failure of chemotherapy and radiotherapy are all too common, and many patients die soon after diagnosis. Here, we make the case for the increased use of molecular imaging in PDAC preclinical research and in patient management.
有效的胰腺癌治疗仍然具有挑战性,特别是胰腺导管腺癌(PDAC)的治疗,它占所有胰腺癌的 95%以上。晚期诊断以及化疗和放疗的失败都太常见了,许多患者在诊断后不久就去世了。在这里,我们提倡在 PDAC 的临床前研究和患者管理中更多地使用分子成像。